Antihistamine switch petition gains support
This article was originally published in The Tan Sheet
Executive Summary
Consumers Union, the non-profit publisher of Consumer Reports, supports a recent petition by law firm Greenberg Traurig to switch Rx antihistamines Allegra (Aventis) and Zyrtec (Pfizer) to OTC status in a letter to FDA July 11. "The consumer cost benefit of having these drugs available over-the-counter outweigh any possible risks," Consumers Union says, adding the move would be consistent with FDA switch policy. "Specifically, the potential for misuse and abuse is low, consumers can use the drugs for self or previously diagnosed conditions, the drugs can be adequately labeled, and health practitioners are not needed to provide for the safe and effective use of the products," the group notes. In its petition to FDA March 12, Greenberg Traurig cited previous citizen petitions in pressing the agency to switch the drugs (1"The Tan Sheet" March 26, 2007, p. 3) ...
You may also be interested in...
Antihistamine Forced Switch Proposal Returns In Citizen Petition
A law firm seeks to cut its own health care costs as well as direct FDA's attention to previous citizen petitions to switch Rx antihistamines to OTC with a petition asking FDA to switch Sanofi-Aventis's Allegra and Pfizer's Zyrtec
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.